**Guideline Page and Request**

<table>
<thead>
<tr>
<th>MPM-A 1 of 2</th>
<th><strong>Panel Discussion/References</strong></th>
<th><strong>Institution Vote</strong></th>
</tr>
</thead>
</table>
| External request: Submission from Merck, requesting the addition of pembrolizumab in the treatment of advanced MSI-H mesothelioma as a category 2A. | Based upon review of the data in the noted references, the panel consensus did not support the addition of pembrolizumab in the treatment of advanced MSI-H mesothelioma. There is insufficient evidence to support the request.  
  - See Submission for references. | 0 | 27 | 0 | 4 |

| MPM-A 1 of 2 | External request: Submission from Novocure, requesting the addition of TTFields as a treatment option for appropriate patients with malignant pleural mesothelioma in combination with pemetrexed and platinum-based chemotherapy. | Based upon review of the data in the noted references, the panel consensus did not support the addition of TTFields as a treatment option for appropriate patients with malignant pleural mesothelioma in combination with pemetrexed and platinum-based chemotherapy. There is insufficient evidence to support the request.  
  - See Submission for references. | 0 | 27 | 0 | 4 |

| MPM-A 1 of 2 | External request: Submission from Genentech, requesting the addition of atezolizumab in combination with bevacizumab as a systemic treatment option for patients with relapsed or refractory and unresectable Malignant Peritoneal Mesothelioma (MPeM). | The panel consensus did not support the addition of atezolizumab in combination with bevacizumab as a systemic treatment option for patients with relapsed or refractory and unresectable MPeM. This is outside of the current scope of the Guidelines. The Panel plans to address the management of MPeM in a future version update.  
  - See Submission for references. | 0 | 27 | 0 | 4 |

| MPM-A 1 of 2 | External request: Submission from Bristol Myers Squibb, requesting review of data for nivolumab plus ipilimumab compared to chemotherapy (pemetrexed plus either cisplatin or carboplatin) as a first-line treatment in patients with unresectable malignant pleural mesothelioma. | Based upon review of the data in the noted references, the panel consensus did not support the addition of nivolumab plus ipilimumab as a first-line treatment in patients with unresectable malignant pleural mesothelioma at the September 4, 2020 meeting. Note that the panel did add this regimen to V2.2020 of the NCCN Guidelines for Malignant Pleural Mesothelioma after FDA approval of nivolumab/ipilimumab for this indication (see Transparency from 10/9/2020).  
  - See Submission for references. | 0 | 27 | 0 | 4 |